Source:

Press Release

April 07, 2021
1 min read
Save

FDA approves Bausch + Lomb's ClearVisc OVD

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device has received FDA approval for use in ophthalmic surgery, according to a press release.

ClearVisc protects the cornea from thermal and mechanical damage, and contains sorbitol, which delivers free radical protection, decreasing risk of corneal damage and decompensation during cataract extraction and implantation of IOLs, according to the release.

The product was tested in a multicenter randomized clinical study of 372 subjects. ClearVisc produced no serious adverse events and met its primary safety and efficacy endpoints.

"OVDs play a critical role in cataract surgery as well as many other ophthalmic surgeries,” Joe Gordon, U.S. president of Bausch + Lomb, said in the release. “ClearVisc offers significant advantages that can help surgeons deliver the best possible outcomes for their patients."